Article

Allergan has launched the first and the only FDA-cleared device TrueTear® to temporarily increase tear production in adult patients with inadequate tear production.

You have read of your 8 free articles this month.

Subscribe to
Medgenera All-Access

Enjoy unlimited access to all contents, resources, exclusive market research reports, databases, surveys and many more features by subscribing to Medgenera All-Access.

Access articles & resources worth up to US $4, 000 per month.

Register with your email to read the full article.

This article is FREE for you! Unlock the unlimited access by subscribing to Medgenera All-Access.

More in BRIEFING


BRIEFING

First-of-its-Kind FDA-Cleared Device Launched to Enhance Tear Production

Allergan has launched the first and the only FDA-cleared device TrueTear® to temporarily increase tear production in adult patients with inadequate tear production.

BRIEFING

Novel EGFR Lung Cancer Drug, Dacomitinib Gains FDA Priority Review

The understanding of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) has been evolved over years. TKIs are found ...

BRIEFING

AstraZeneca Spinout Viela Bio Fetches $250 M, Pushes Pipeline Autoimmune Drugs in Clinical Study

AstraZeneca subsidiary, MedImmune has spun out a new inflammation- and autoimmunity-focused biotech, Viela Bio with six molecules from MedImmune. The ...

BRIEFING

FDA Approves Glatopa, Generic Version of Teva’s Top-Selling Multiple Sclerosis Drug Copaxone

US FDA approved Glatopa®, generic version of Teva’s Copaxone developed by Sandoz (Novartis’ biosimilar division) in collaboration with Momenta Pharma. ...

Most Popular


GROW

7 New Ideas to Start a Healthcare Business in India (2018)

Highlights Herein, we are proposing the seven new healthcare business ideas in India in 2018 which are based on our ...

NEWLY PUBLISHED

Pharma Patents: Can India Reward Incremental Innovation?

Chandramouli Natarajan is an Associate Scientist, Ricon pharma LLC, Denville, USA. He has presented his opinion and views on the Pharmaceutical patents issues in India. This article is available for free to read and share.

Leave a reply